Tag:

Hepatitis C

Latest Headlines

Latest Headlines

Hep C patient sues Blue Cross for blocking access to Harvoni

A patient denied the latest hepatitis C drugs has sued her insurance company. In this case, it's Anthem Blue Cross, and the California plaintiff says her plan blocked her from treatment because she's not sick enough to qualify under its rules.

Merck and Gilead square off in battle of the next-next-gen hep C combos

Early today both Gilead and Merck issued new data on their next-next-gen hepatitis C combos, demonstrating just how brutal the competition for market share is becoming while highlighting some of the boundaries that are emerging in shortening treatment regimens.

AbbVie moves closer to Japan's crowded hep C field with priority review nod

AbbVie's used to heavy hep C competition thanks to combo drug Viekira Pak, which has squared off against Gilead's Harvoni in the U.S. But now, the Illinois drugmaker is one step closer to a hep C approval in Japan, where it'll be a whole different ballgame.

Record new drug sales give a mega-boost to U.S. drug spending

Given the flood of numbers on hepatitis C treatment costs, it's no surprise that U.S. drug spending took a leap last year. Given the news on specialty drug prices, it's no surprise that the biggest share of that growth came in that category of medications.

Currency hurts, Olysio plummets, but J&J pharma growth carries on

Johnson & Johnson revealed that its hepatitis C drug Olysio succumbed to U.S. competition. With Gilead Sciences' two-in-one pill Harvoni and AbbVie's Viekira Pak now on the scene, the J&J drug saw sales drop by two-thirds--and it was one of J&J's biggest pharma-growth drivers last year.

Medicare takes $4.5B cost hit from superstar hep C treatments

Industry watchers knew Medicare would be shelling out a whole lot more on hepatitis C treatments last year, thanks to new-and-improved drugs. But just how much more did it cough up?

Bristol-Myers heads back to the FDA with its long-delayed hep C drug

Bristol-Myers Squibb is finally in line for FDA approval for its once-rejected hepatitis C daclatasvir, angling to take third place among companies with next-generation cures for the virus.

Drug spending surged 13% last year, with pricey hep C meds leading the charge

U.S. prescription drug spending shot up 13.1% last year, according to a new report from Express Scripts. And the vocal price critic says it knows just who's to blame.

Gilead strikes Sovaldi price deal in Germany as it picks up speed in EU

Just days after Gilead COO John Milligan told investors to expect negotiations for its hep C franchise to unfold very quickly in Europe, Germany has said it has a deal to buy Sovaldi at €41,000 for a 12-week course. That is deeply discounted from the initial price of €56,500 with which the company started.

Breakthrough? Not anymore says FDA as Bristol-Myers joins Merck in hep C's coach section

Merck's not the only big player in the hepatitis C competition to face losing bragging rights to the FDA's "breakthrough" drug designation for a late-stage program. It turns out that Bristol-Myers Squibb, another laggard in the race to hatch new therapies for the virus, also finds its daclatasvir on the FDA's chopping block.